BioVaria's technologies were presented as an all-day poster exhibition that enables industry representatives to gain a unique overview of undiscovered, licensable technologies and to discuss scientific details face-to-face with the inventors.
Additionally half of the technologies (marked with a *) have also been be presented as 10-min talks.
|
| Cardio-Vascular |
|
| ipal |
I1* Charité – University Medicine, Berlin
Method of Producing Homologous Cellular Blood Components from Hematopoietic Progenitor Cells |
 |
| ipal |
I2 Humboldt University Berlin
Microginin synthetase – Gene cluster and application
in the biocombinatoric |
|
| ipal |
I4* Charité – University Medicine Berlin
Method for the Identification of Urotensin IIConverting
Enzyme Inhibitors |
|
| NGFN |
N4 Helmholtz Zentrum München
Novel marker for chronic heart disease |
|
|
| Clinical Chemistry |
|
| EMBLEM |
E2 European Molecular Biology Laboratory, Monterotondo
HT-Method for producing
monoclonal antibodies |
|
| DKFZ |
D3* Deutsches Krebsforschungszentrum, Heidelberg
Versatile method to link diagnostics and/or
therapeutics to biomolecules |
|
|
| Drug delivery |
|
| EMBLEM |
E4 University Clinic Heidelberg, Germany
Peptides as vehicles for specific delivery of compounds to the liver |
|
|
| Drug screening/testing |
|
| Fraunhofer VLS |
F1* Fraunhofer IGB
From Model Tissues towards Functional Organs |
|
| Fraunhofer VLS |
F2* Fraunhofer IGB
In vitro human Skin Test System |
|
| Fraunhofer VLS |
F3 Fraunhofer ITEM
Development of a Procedure for High Content and
Higher Throughput Analysis of DNA-Damage based on the COMET-Assay |
|
| Medigate |
M4 Universitätsklinikum Hamburg-Eppendorf
Functional target validation for cardiac insufficiency based on the Engineered Heart Tissue (EHT) technique |
|
|
| Immune/Autoimmune |
|
| PROvendis |
P2* University of Bonn
GEF-inhibitors for the modulation of immune response and insulin signalling |
|
| PROvendis |
P4 University of Bonn
Non-nucleotide agonists of the P2Y11-receptor with immuno-suppressant effect |
|
| NGFN |
N5 Max Delbrück Center for Molecular Medicine
Intracellular Target for Systemic Lupus Erythematodes (SLE) |
|
|
| Infection |
|
| Ascenion |
A1* Heinrich-Pette Institute
Piperidone derivatives for treatment of HIV and HTLV infections and of Chronic Myeloid Leukemia |
|
| Ascenion |
A3* Hans-Knöll Institute
Novel antibiotics for the treatment of Methicillin-resistant Staphylococcus aureus |
|
| Ascenion |
A5* Helmholtz Centre for Infection Research
Highly potent adjuvants for mucosally administrable vaccines |
|
| EMBLEM |
E3* European Molecular Biology Laboratory, Grenoble
Influenza:
New Target & Compounds |
|
| Rubitec |
U5 Ruhr-University, Bochum
RSV-Vaccine: Vaccine based on adenoviral vectors preventing infection with the respiratory syncytial virus |
|
| |
U7 Universität Zurich, MPI für Molekulare Genetik Berlin
Gene silencing of viruses (HIV) by short
double-stranded DNA |
|
| VPM |
U2* Vakzine Projekt Management GmbH
Soluferon® a 2nd generation Interferon-ß with increased Bioavailability for the Treatment of Multiple Sclerosis and Viral Diseases |
|
|
Inflammation |
|
| PROvendis |
P1* University of Bonn and Düsseldorf
Phosphorylated A2A receptor agonists as anti-inflammatory agents with improved tolerance |
|
| DKFZ |
D1 Deutsches Krebsforschungszentrum Heidelberg
DMBT-1 for the treatment
of Crohn’s disease |
|
| ipal |
I3* Charité – University Medicine Berlin
Nematode Derived Cystatin Inhibits Allergic Airway
Responses and Inflammation |
|
|
| Metabolism |
|
| PROvendis |
P3* University of Bonn
Ex vivo-diagnosis and prognosis
of early diabetic retinopathy |
|
| NGFN |
N2 German Institute of Human Nutrition (DIfE)
A novel marker in the response to dietary fat, obesity and diabetes |
|
|
| Neurological disorders |
|
| NGFN |
N1 Helmholtz Zentrum München, University Clinic Tübingen
LRRK2 – novel target for Parkinson’s Disease
and Parkinson-related Syndroms |
|
| EMBLEM |
E5* University Clinic Heidelberg
New diagnostic biomarkers and therapeutic approaches for irritable bowel syndrome – IBS
|
|
|
| Oncology |
|
| Ascenion |
A2 Hans-Knöll Institute
Novel cytotoxic and cytostatic substances for the treatment of cancer |
|
| Ascenion |
A4* Helmholtz Centre for Infection
MALP-2 – a multitalent for the treatment of cancer, infections, wound healing and autoimmune diseases |
|
| PROvendis |
P5 Universities of Bonn and Düsseldorf
Glio-Methyl- predictive epigenetic parameter
for gliomas |
|
| EMBLEM |
E1 European Molecular Biology Laboratory, Heidelberg/Monterotondo & Rigshospitalet, Copenhagen
Novel biomarkers for detection of testicular
carcinoma in situ and derived cancers in human samples |
|
| DKFZ |
D2* Deutsches Krebsforschungszentrum, Heidelberg
Drug Candidate for Treating Advanced Stage Neuroblastoma |
|
| DKFZ |
D4 Deutsches Krebsforschungszentrum, Heidelberg
Palladium compounds
for cancer therapy |
|
| DKFZ |
D5* Deutsches Krebsforschungszentrum, Heidelberg
Targeting SGT to eliminate
undesired cell populations |
|
| ipal |
I5 Charité – University Medicine Berlin
Novel Titanocenes as Anti-Tumor Agents |
|
| NGFN |
N3 Max Planck Institute of Biochemistry
Poloxin: a polo-like kinase PBD inhibitor |
|
| BayPAT |
U1 Ludwig-Maximilians-Universität, München
Inhibition of uPAR by siRNA in the treatment of malignant melanoma |
|
| Elara |
U4 Elara Pharmaceuticals GmbH
Tubulin polymerization inhibitors and allosteric Aurora A kinase inhibitorss |
|
| Rubitec |
U6 Ruhr-University, Bochum
Synthetic Inhibitors for Ras-Raf Mediated Signal Transduction |
|
| Medigate |
M2 Universitätsklinikum Hamburg-Eppendorf
Innovative Doxycycline-Regulated Adenoviral Vectors
for Safe and Highly Efficient Transgene Expression in Tumors |
|
| VPM |
U3* Vakzine Projekt Management GmbH
VPM4001 a Therapeutic Allogeneic Vaccine against Prostate Cancer |
|
| BayPAT |
U8* Ludwig-Maximilians-Universität, München
Small Molecule XIAP Inhibitor
(B64017) |
|
| R&D |
U9 R&D-Biopharmaceuticals GmbH
Tubulysins and Epothilones – promising natural products classes for applications in oncology |
|
|
| Tissue engineering |
|
| Medigate |
M1* Universitätsklinikum Hamburg-Eppendorf
Method for Carrying Out the ex vivo Expansion and Differentiation of Multipotent Stem Cells |
|
| Medigate |
M3* Universitätsklinikum Hamburg-Eppendorf
Engineered Heart Tissue (EHT) |
|
| Medigate |
M5* Universitätsklinikum Hamburg-Eppendorf
BioVAD – a Biological Ventricular Assist Device |
|
|
